No Data
No Data
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
Atea Pharmaceuticals: Radoff-JEC Group Has Agreed to Vote All of Shrs It Collectively Owns in Favor of Each of Atea's Bd Nominees at 2025 Annual Meeting >AVIR
Atea Pharmaceuticals Enters Into Agreement With Bradley L. Radoff and Michael Torok >AVIR
Express News | Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock
Express News | Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $6